title: A population-based study on management of prostate cancer in four regions of France.
abstract: In France, as in other European countries, management of prostate cancer in the population is rather variable. The objective was to analyse diagnosis and treatment modalities of prostate cancer in patients from French cancer registries.A sample of 803 patients with prostate cancer diagnosed in 1995 was drawn at random from cases recorded in four cancer registries in the geographical regions of Bas-Rhin, Calvados, Isère and Tarn. Diagnosis, clinical staging and treatment were analysed by questionnaire. Multivariate analysis by logistic regression was used to describe medical determinants (age, PSA, clinical staging) of the various treatment choices.The mean age of the patients was 71.6 y (range 46-94 y). Clinical staging showed 60% T(1-2) tumours, 15% T(3-4) and 17% N+or metastases. PSA rate (median 18.2 ng/ml) was assessed in 92.4% of patients. Prostate cancer was diagnosed by prostate biopsy in 63% and by transurethral resection of the prostate (TURP) in 32% of patients. The main treatments were radical prostatectomy 22%, radiotherapy 19.4%, hormonal therapy 33%, TURP alone 17.7% and expectant management 6%. The method of treatment was unknown in 5.7% of cases. Adjuvant radiotherapy or hormonal therapy had been used in 31% of cases. Logistic regression analysis showed that radical prostatectomy was most often performed in patients aged <60 y, three times more frequently for T(2) tumour and for PSA between 4 and 20 ng/ml. Radiotherapy was the most frequently applied treatment for patients aged between 65 and 75 y, especially in T(3) tumours.Approximately 75% of the patients in the study underwent a specific treatment for prostate cancer with a curative intention in 40%. This study provides a baseline to clinicians and public health authorities on the management of prostate cancer in France with recent data. This survey will be useful to compare future descriptive analysis and to provide data regarding changing clinical practice.Prostate Cancer and Prostatic Diseases (2001) 4, 154-160.
authors.affiliation: [1] Comité de Cancérologie de l'Association Française d'Urologie, France [2] INSERM U518, Faculté de Médecine, Toulouse, France.
authors.forename: M
authors.initials: M
authors.lastname: Soulié
authors.forename: P
authors.initials: P
authors.lastname: Grosclaude
authors.forename: A
authors.initials: A
authors.lastname: Villers
authors.forename: F
authors.initials: F
authors.lastname: Ménegoz
authors.forename: P
authors.initials: P
authors.lastname: Schaffer
authors.forename: J
authors.initials: J
authors.lastname: Mace-Lesec'h
authors.forename: L
authors.initials: L
authors.lastname: Molinier
authors.forename: M
authors.initials: M
authors.lastname: Sauvage-Machelard